FDA Brief

Warning letters Drugs

FDA warning letter to

3D Imaging Drug Design and Development LLC

High riskIssued Dec 4, 2025Posted Dec 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warns 3D Imaging of CGMP failures in sterile PET drug manufacturing and outdated drug listings.

What happened

FDA inspected 3D Imaging's Little Rock facility from June 9 to 13, 2025, and found aseptic connections made in an open benchtop area, a hot cell in poor repair, inadequate environmental monitoring, exposed operator skin and hair during manufacturing, and poor sterility testing technique. FDA also reviewed the firm's drug listing submissions and found that Fludeoxyglucose F18 was not updated or certified as required.

What FDA found

  1. The facility was not adequate to prevent contamination, including aseptic connections in an open benchtop area and rust and residue in the hot cell near where sterile product is filtered into vials.

    21 CFR 212.30(a) and (b)
  2. Environmental monitoring was inadequate because the hot cell where FDG is filtered into final vials was not monitored and the alert and action levels were not appropriate.

    21 CFR 212.30(a) and (b)
  3. Production and process controls were inadequate because operators had exposed skin and hair during manufacturing and two operators had not been requalified by media fill at least annually.

    21 CFR 212.50
  4. Laboratory methods were inadequate because sterility testing was performed with poor aseptic technique and test tubes were shaken before reading, which may mask results.

    21 CFR 212.60
  5. The drug listing for Fludeoxyglucose F18 was not updated or certified as required.

    section 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207
  6. The drug listings for Ammonia N 13 and Sodium Fluoride F-18 also had not been updated or certified.

    section 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207

What FDA wants

FDA asks the company to respond in writing within 15 working days, correct the violations promptly, and provide detailed remediation plans and updated drug listings.

Who should pay attention

  • hospitals and imaging centers that use PET drugs
  • PET drug manufacturers and aseptic processing operators
  • distributors and prescribers of FDG and other PET radiopharmaceuticals

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk